Objectives-The maintenance of articular cartilage integrity during long term treatment with non-steroidal antiinflammatory drugs (NSAIDs) is of clinical importance. These experiments were set up to test the action of tenidap, naproxen, and diclofenac on bovine and porcine cartilage, matrix synthesis, and catabolism. Methods-Short term organ culture techniques were used to determine the effect of interleukin 1 (IL-1) on synthesis and degradation, and the action oftenidap and the other drugs on these parameters. The retention of glycosaminoglycans (GAGs) and the synthesis of GAGs by incorporation of sulphur-35 labelied sulphate was used to determine the chondrocyte metabolic activity.
were set up to test the action of tenidap, naproxen, and diclofenac on bovine and porcine cartilage, matrix synthesis, and catabolism. Methods-Short term organ culture techniques were used to determine the effect of interleukin 1 (IL-1) on synthesis and degradation, and the action oftenidap and the other drugs on these parameters. The retention of glycosaminoglycans (GAGs) and the synthesis of GAGs by incorporation of sulphur-35 labelied sulphate was used to determine the chondrocyte metabolic activity. Results-The action of human recombinant interleukin lot (hrIL-lo) in increasing catabolic activity and inhibiting synthetic activity of the animal cartilages was confirmed. Tenidap was shown to give substantial and significant protection against the catabolic effects of hrIL-lox and, to a lesser degree, against the inhibition of matrix synthesis by the cytokine. Neither diclofenac nor naproxen in doses expected to occur in the synovial fluid showed this action. Tenidap also inhibited the GAG loss from cocultures and, to a moderate degree, reversed the inhibition of synthesis by synovial tissue. Tenidap also stimulated cartilage repair activity during recovery from IL-1 treatment. The optimum concentration of the action against IL-1 was between 5 and 10 ,ug/ml. Above this concentration tenidap itself showed some inhibitory action on GAG synthesis. Conclusions-Bearing in mind the problems in extrapolating from in vitro work on animal cartilages to humans, it seems possible that tenidap may be useful in decreasing the deleterious action of cytokines such as IL-1 on cartilage integrity during arthritic disease and in stimulating chondrocyte repair processes. Cartilage chondrocytes maintain a dynamic equilibrium in their extracellular matrix throughout life by synthesising and degrading structural macromolecules. In disease, however, the rate of breakdown may exceed the rate of formation, with net loss of material ensuing. It is now recognised that these processes may be controlled by local cytokine messengers from adjacent cells and tissues of the adult joint."A The most extensively studied of these cytokines, interleukin lot (IL-la), may have a function in controlling articular integrity in inflammatory arthritis and in the slower osteoarthritic process.57
In rheumatoid arthritis the breakdown of cartilage adjacent to the pannus is thought to be due to proteolytic enzymes secreted by inflammatory cells, by stimulated cells of the invading and proliferating synovium, and by activated chondrocytes. The IL-lcx and other cytokines produced by the inflammatory cells and fibroblasts of the synovium may stimulate cartilage breakdown and inhibit the synthesis of cartilage matrix by indigenous chondrocytes. This inhibition may be more important in the slower processes seen in osteoarthritis, where it is suggested that the local episodic release of cytokines causes a net loss of proteoglycan and, eventually, collagen8-1 by inhibiting the normal matrix repair processes. There is clinical and biological evidence that cartilage repair can take place,'2 13 but it is unfortunate that a number of powerful anti-inflammatory drugs which are used in the treatment of arthritic diseases may depress cartilage synthetic activity."417 It is necessary, therefore, to ensure that new antiinflammatory drugs do not interfere with the normal repair processes. If such drugs could also be shown to decrease the activity of cytokines in causing articular cartilage damage, they could be of substantial value in the long term treatment of patients with arthritis.
The experimental antiarthritic drug tenidap has been shown to lower the production of a number of inflammatory mediators including IL-la. 18 19 In the light of these results tenidap was tested in in vitro cartilage organ culture assays to determine its effect on the catabolic and anabolic activity of indigenous chondrocytes. Experiments were also set up using bovine and porcine cartilage to determine whether tenidap was capable of protecting cartilage from the direct activity of human recombinant IL-lot (hrIL-lcx) and from the destruction mediated by adjacent synovial tissue.
Patients and methods

ORGAN CULTURE TECHNIQUES
Techniques were based on the methods of Dingle et al. 20 Porcine cocultures were set up as described by Fell and Jubb,2' whereas bovine cocultures were a development of the method of Dingle.2"
The porcine cartilage was obtained from the Effect of tenidap on cartilage integrity in vitro chondyles of the metacarpophalangeal joints of adolescent pigs freshly killed at a commercial abattoir. The synovial tissue was obtained from the same joint and chopped into small pieces before use. The cartilage was usually cultured in 4 X 2 X 1 mm segments, six segments being obtained from each pig's trotter. In porcine coculture approximately 5 mg wet weight synovial tissue was used.
The bovine cartilage was obtained from 1 mm slices of the nasal septum of adult cows freshly slaughtered at an abattoir from which 4 mm discs or annuli were cut out using a modified commercial leather punch; 150 replicates could be obtained from a single nasal septum. Figure 1 shows that bovine cartilage in organ culture had a rapid turnover of matrix GAG and was susceptible to the action of hrIL-lot (2 ng/ml) and to cocultivation with synovial tissue. Thus, although the controls contained 70% of the starting material after eight days in culture, in the presence of hrIL-l o or synovial tissue this was reduced to only 8%. Porcine cartilage ( fig 2) had a lower GAG turnover rate; controls contained 86% of the GAG content after eight days in culture. Porcine cartilage was also less susceptible to the action of hrIL-o1c and cocultivation with synovial tissue than bovine cartilage. The spontaneous GAG loss from porcine and bovine cartilage in culture was decreased significantly (p<OOO1) by 20 ,ug/ml tenidap and 5-20 ,ug/ml tenidap gave significant (p<0 01) protection against GAG loss induced by hrIL-lct in bovine and porcine cultures and porcine coculture. In addition, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Figure 3 shows that 2 ng/ml hrIL-la produced between 75 and 85% inhibition of GAG synthesis in porcine articular cartilage. The effect of tenidap on this inhibition and a comparison of its effect with two NSAIDs (diclofenac and naproxen) is also shown. Tenidap, at 5 and 10 ,ug/ml, gave statistically significant (p<0001) protection from the action of 2 ng/ml hrIL-la. The rate of 4 incorporation was increased threefold in the presence of these concentrations of tenidap. This effect was not seen at 20 ,ig/ml, a result consistent with these data. Neither diclofenac (0-1-1-0 ,ug/ml) nor naproxen (12.5-100 ,mg/ml) showed any evidence of protection against the inhibitory effect of hrIL-la. The concentration ranges chosen for these drugs were based on the known levels present in serum/synovial fluid during treatment of human disease. 24 Figure 4 shows a comparison of the effects of tenidap, diclofenac, and naproxen on GAG retention in porcine cartilage treated with 2 ng/ ml hrIL-la. In this experiment tenidap showed significant (p<0 01) inhibition of hrIL-la induced GAG loss at doses of 2-5-20 ,ug/ml.
At 5 jig/ml tenidap protection, although significant (p<001), was not as great as that seen in the previous experiment, whereas at the highest levels the results were similar to those seen in fig 2. Neither diclofenac nor naproxen gave any evidence of protection against GAG loss induced by the cytokine. 0o .g/ml naproxen + hrlL-la 1 25 ,.g/ml tenidap + hrIL-loa El 0.1 ,ug/ml diclofenac + hrIL-la 12-5 jig/ml naproxen + hrIL-la 2-5 jig/ml tenidap + hrIL-la 0-25 ,ug/ml diclofenac + hrIL-la 25-0 A g/ml naproxen + hrIL-la 5-0 jig/ml tenidap + hrIL-la 0-5 ,ug/mI diclofenac + hrIL-la 50-0 ,ug/ml naproxen + hrIL-la 10 .0 .Lg/ml tenidap + hrIL-la 2 1*0 ,ug/ml diclofenac + hrIL-la 100-0 ,g/ml naproxen + hrIL-la B 20 .0 ,g/mI tenidap + hrIL-la Tenidap Diclofenac Naproxen Figure 3 Effect of tenidap, diclofenac, and naproxen on porcine cartilage glycosaminoglycan synthesis in the presence ofhuman recombinant interleukin la (hrIL-lot). Porcine cartilage. In these experiments porcine articular cartilage ree times was treated with 2 ng/ml hrIL-Ia. for four days, as in the either with or without tenidap, diclofenac, or t tenidap naproxen, and then cultured for a further four cartilage, days without hrIL-lot, with or without the chondro-drug. The parameters of recovery were the could be GAG content of the tissue and the 35SO2 )f tenidap incorporation into GAG as a measure of n 1 25 to chondrocyte matrix synthetic activity. As a preliminary to these experiments, the effect of tenidap on untreated cartilage medium for a further four days was investigated. Figure 6 shows that tenidap did not significantly influence the GAG content of the tissue during this experimental procedure. There was, ** however, a statistically significant (p<0.01) T\\\ increase in the synthetic activity of the cartilage as expressed by the incorporation of 35SO4-at the higher concentrations of the drug (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) ug/ml); an observation which should be compared with the data in fig 7 .
EFFECT OF TENIDAP ON SYNOVIAL METABOLIC ACTIVITY
In the first hrIL-lcx experiment the tissue was treated with 2 ng/ml hrIL-lot for four days and tissue was then cultured in control medium without hrIL-lac but in the presence ofvarious concentrations of tenidap. Figure 7A shows that, at between 2-5 and 5 ,ug/ml tenidap, there was a marked increase in the synthetic activity of the tissues compared with controls, and this was reflected in the increased GAG concentrations. This effect on synthesis was not seen at the highest concentration of the is). Dead drug (20 ,ug/ml). In the second recovery cured with experiment the tissue was treated with hrIL-l ot um for eight plus tenidap at various concentrations for four O ,ug/ml tenidap + hrIL-lce D 0 ,ug/ml diclofenac + hrIL-lce O ,ug/ml naproxen + hrIL-lcx 1-25 ,ug/ml tenidap + hrIL-la 0-1 ,ug/ml diclofenac + hrIL-lcx 12 5 ,ug/mI naproxen + hrIL-l( 2 5 ,ug/ml-tenidap + hrIL-la 0-25 ,ug/ml diclofenac + hrIL-lc( 25-0 ,ug/ml naproxen + hrIL-lac 5 0 ,ug/ml tenidap + hrIL-lot 0-5 ,ug/ml diclofenac + hrIL-la 50.0 ,ug/ml naproxen + hrIL-loa 10-0 ,ug/ml tenidap + hrIL-la 1-0 ,ug/ml diclofenac + hrIL-lot 100 0 ,ug/ml naproxen + hrIL-la 20 .0 ,ug/ml tenidap + hrIL-lce Tenidap (pLg/ml) Figure 7 Effect of tenidap on recovery ofporcine cartilage after human recombinant interleukin lc (hrIL-la) induced damage. Porcine cartilage strips (4x2X 1 mm) were cultured with Dulbecco's modified Eagle's medium plus 5% fetal calf serum forfour days in the presence of (A) 2 ng/ml hrIL-la and no tenidap, or (B) 2 days, these results reflect the activity after four days of recovery. This indicates that tenidap, certainly in the middle dose range, appeared to improve the recovery of the tissue after hrIL-loc insult.
Naproxen and diclofenac were tested under the same experimental conditions but neither drug had any influence on recovery in terms of the GAG content of the tissue or the rate of 4 incorporation, unlike the results seen with tenidap.
Discussion
These experiments were undertaken to determine whether it was possible to modulate cartilage damage. In vitro organ culture techniques were chosen because it has been shown that the reactions of intact cartilage in organ culture correspond closely to those seen in animal experiments. For example, hrIL-1 (, which increases chondrocyte catabolic reactions and inhibits chondrocyte matrix synthetic mechanisms, will, when administered in vivo, produce similar results.'3
The two in vitro methods of inducing cartilage damage, namely hrIL-l1a treatment and coculture with synovial tissue, were used because it was considered that the cytokine had a direct role in the mechanism of cartilage damage in osteoarthritis and also as part of the complex modulation system for the synovial inflammation characteristic of rheumatoid arthritis."4 6 In inflammatory arthritis the catabolism of articular cartilage is believed to be due to the activation of the indigenous chondrocytes and to the action of extrinsic proteolytic enzymes and possibly free radicals from the adjacent synovial tissue. The synovial/ cartilage cocultures were developed by Fell and Jubb2' as an in vitro model for this effect.
Although these types of catabolic reactions have been extensively studied, the observation that human articular cartilage synthesis is susceptible to inhibition by low doses of hrIL-lot and by certain NSAIDs'4 must be considered in the formulation of treatment strategies for chronic rheumatic disease. It seems likely that not all NSAIDs have the same pharmacological properties in terms of cartilage damage. It is important to determine whether any new antiarthritic drug should, at least, not prevent the active repair processes that are possible.'2 13 For this reason the present experimental work not only compared the action of tenidap-a new cytokine modulating antirheumatic drug-with the NSAIDs diclofenac and naproxen directly on cartilage metabolism, and on the modulation of hrIL-1 a activity, but also investigated the repair of articular cartilage after hrIL-loa induced damage in the presence of the three drugs.
The experiments confirmed that, in the two species tested, hrIL-1 t and synovial tissue caused the degradation of cartilage matrix and inhibited matrix synthesis. Tenidap was shown to give substantial and significant protection against the catabolic effect of hrIL-lox. There was, to a lesser degree, some protective effect in the middle dose range against the inhibition of synthetic activity by hrIL-1 a and by synovial tissue. At the highest dose of tenidap tested there was inhibition of "SO'-incorporation into GAGs, but curiously this effect was not confirmed when [3H]glucosamine was used as a marker of GAG synthesis. Neither of the two NSAIDs tested had any protective action on the integrity of the cartilage matrix nor on the ability of chondrocytes to synthesise GAG in the presence of hrIL-lot. Tenidap showed some beneficial effect when recovery after hrIL-l1a treatment was studied, either when administered together with the hrIL-1 a, or subsequently. Normal tissue treated with tenidap and then allowed to metabolise in the absence of the drug showed no deleterious effects, even at the highest concentration of tenidap. The optimum tenidap concentration for protection against hrIL-la and for encouraging recovery from the damaging effects of the cytokine, without itself inhibiting synthesis, appears to be between 5 and 10 ,ug/ml in these animal cartilages. This narrow band suggests that careful dose control would be needed to obtain this effect in vivo.
Caution must be exercised in any extrapolation from in vitro to in vivo situations and from work on animal cartilage to possible effects on human cartilage. In particular, the lack of catabolic action of IL-1 on human cartilage" suggests that the drug's action on matrix synthesis is of greater importance than the inhibition of catabolism. It seems possible that if concentrations of tenidap between 5 and 10 ,ug/ml in the synovial fluid can be achieved (synovial fluid concentrations in this range have been observed during treatment of patients with daily doses of 120 mg27), this could have an action on the inhibition of matrix synthesis by hrIL-la, thus allowing natural repair processes to take place.
In addition to its reported activity in decreasing hrIL-1 a production by macrophages and monocytes, '8 19 tenidap has three potentially useful functions in the modulation of articular damage. Firstly, tenidap may prevent the action of cytokines in causing cartilage catabolism in some patients. Secondly, tenidap may be useful in increasing the synthetic and repair activities of damaged cartilage. Finally, from the coculture experiments, it appears that tenidap may modulate the release of chondrolytic enzymes from adjacent synovial tissue.28
The last result suggests the possibility that tenidap could modulate disease activity in inflammatory arthritis where pannus erosion of cartilage plays a significant part in joint damage. The absence of activity observed with diclofenac and naproxen implies that the prevention of chondrolysis shown in the presence of tenidap was not a result of inhibition of cyclo-oxygenase. The inhibition of IL-loa bioactivity previously reported using tenidap, perhaps mediated via 5-lipoxygenase inhibition, may account for the activity of tenidap observed in this study. Current experimental work using the drug on normal and osteoarthritic human cartilage and rheumatoid arthritis synovium in organ culture may help to resolve these questions.
